NEW YORK , Oct. 21, 2024 /PRNewswire/ -- Report with the AI impact on market trends- The global sexually transmitted disease (STD) testing market size is estimated to grow by USD 32.37 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of over 5.6% during the forecast period. Increasing prevalence of stds is driving market growth, with a trend towards advances in rapid diagnosis of stds.
However, limited healthcare services in developing regions poses a challenge. Key market players include AbbVie Inc., AccuBioTech Co.
Ltd., AdvaCare Pharma, BIOGENIX Inc. Pvt.
Ltd., CTK Biotech Inc., Everlywell Inc.
, F. Hoffmann La Roche Ltd., Gilead Sciences Inc.
, GlaxoSmithKline Plc, Goffin Molecular Technologies, Hangzhou Biotest Biotech, Hologic Inc., Inovio Pharmaceuticals Inc., Johnson and Johnson Services Inc.
, LT Labs, Merck and Co. Inc., Ok Biotech Co Ltd.
, Priority STD Testing, QIAGEN NV, and RayBiotech Life Inc.. Key insights into market evolution with AI-powered analysis.
Explore trends, segmentation, and growth drivers- View the snapshot of this report Market Driver The Sexually Transmitted Disease (STD) testing market is experiencing a notable transition from traditional laboratory methods to rapid point-of-care (POC) testing. POC HIV testing has gained significant acceptance due to its ability to overcome patient and provider barriers to routine screening. Self-testing for HIV through home HIV test kits or in-home settings is increasingly .
